Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Titel:
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Auteur:
Soria, Jean-Charles Felip, Enriqueta Cobo, Manuel Lu, Shun Syrigos, Konstantinos Lee, Ki Hyeong Göker, Erdem Georgoulias, Vassilis Li, Wei Isla, Dolores Guclu, Salih Z Morabito, Alessandro Min, Young J Ardizzoni, Andrea Gadgeel, Shirish M Wang, Bushi Chand, Vikram K Goss, Glenwood D